Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved in the US for the treatment of renal cancer, pancreatic neuroendocrine tumors, and hemangioblastomas in VHL patients [120]. This evidence concerns the gene EPAS1 and renal carcinoma.